Khalil M A M, Khalil M A U, Tan J, Khan T F T
Diaverum Prince Abdul Majeed Renal Centre, Jeddah, Saudi Arabia.
Department of Urology, Institute of Kidney Disease, Peshawar, KPK, Pakistan.
Indian J Nephrol. 2018 Jul-Aug;28(4):257-264. doi: 10.4103/ijn.IJN_251_17.
BK polyomavirus (BKV) is a challenging problem for the transplant nephrologist. Various strategies have been used to prevent or treat BK virus nephropathy (BKVN). These include reduction in immunosuppression, intravenous immune globulin, cidofovir, leflunomide, and the fluoroquinolone antibiotics. All these agents have their own toxicities. Great interest was shown to use fluoroquinolones to prevent BKVN after its useful experience was reported in bone marrow transplant. Fluoroquinolones being cheap and easily available, attracted nephrologists to use it, for prevention of BKVN. These agents have been shown studies to be effective. However, there are mixed results about their effectiveness in prevention of BKVN in clinical setting. This review will focus the evidence available for using fluoroquinolones in prevention of BKVN and its usefulness. Furthermore, a way forward to use these agents or not for prevention of BKVN will also be discussed.
BK 多瘤病毒（BKV）对移植肾病学家来说是一个具有挑战性的问题。已经采用了各种策略来预防或治疗BK病毒肾病（BKVN）。这些策略包括减少免疫抑制、静脉注射免疫球蛋白、西多福韦、来氟米特和氟喹诺酮类抗生素。所有这些药物都有其自身的毒性。在骨髓移植中报道了氟喹诺酮类药物的有益经验后，人们对使用它预防BKVN表现出了极大的兴趣。氟喹诺酮类药物价格便宜且易于获得，吸引了肾病学家使用它来预防BKVN。研究表明这些药物是有效的。然而，关于它们在临床环境中预防BKVN的有效性，结果不一。本综述将聚焦于使用氟喹诺酮类药物预防BKVN的现有证据及其效用。此外，还将讨论是否使用这些药物预防BKVN的未来方向。
